As part of $1B initiative with HHS, J&J looks to dramatically scale up vaccine manufacturing
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Johnson & Johnson is moving to rapidly scale up its manufacturing capacity via a partnership with HHS, with the goal of supplying globally over a billion doses of a vaccine. The initiative is part of a planned $1 billion investment by the company and the agency to co-fund vaccine R&D and clinical testing against COVID-19.
The Biomedical Advanced Research and Development Authority (BARDA), part of HHS, also said it will collaborate with Moderna Inc. (NASDAQ:MRNA) to prepare for late-stage testing of its COVID-19 vaccine, the first to reach the clinic, as well as scale up manufacturing to produce “thousands” of doses for use in clinical trials...